公开(公告)号：US20230248740A1

公开(公告)日：2023-08-10

申请号：US17953867

申请日：2022-09-27

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION ,  NATIONAL CANCER CENTER ,  SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

发明人： Hwan Geun Choi ,  Jong Bae Park ,  Eunhwa Ko ,  Jung Beom Son ,  Nam Doo Kim ,  Seung Hoon Lee ,  Do-Hyun Nam

IPC分类号： A61K31/5513 ,  A61P35/04 ,  A61K31/415 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/506 ,  A61K31/5377 ,  C07K16/22

CPC分类号： A61K31/5513 ,  A61K31/415 ,  A61K31/437 ,  A61K31/506 ,  A61K31/4365 ,  A61K31/5377 ,  A61P35/04 ,  C07K16/22

摘要： Disclosed is a pharmaceutical composition for the prevention or treatment of brain cancer, containing a compound capable of penetrating the blood-brain barrier as an active ingredient, the pharmaceutical composition for the prevention or treatment of brain cancer is capable of efficiently penetrating the blood-brain barrier of the brain to thereby effectively inhibit LRRK2 protein expression, and is thus useful in the prevention or treatment of brain cancer.

公开(公告)号：US11208412B2

公开(公告)日：2021-12-28

申请号：US16488194

申请日：2018-02-22

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION ,  NATIONAL CANCER CENTER ,  SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

发明人： Hwan Geun Choi ,  Jong Bae Park ,  Eunhwa Ko ,  Jung Beom Son ,  Joong-heui Cho ,  Yi Kyung Ko ,  Jin-Hee Park ,  So Young Kim ,  Seock Yong Kang ,  Seungyeon Lee ,  Nam Doo Kim ,  Yunho Lee ,  Sun-Hwa Lee ,  Dayea Kim ,  Sun Joo Lee ,  Jae Hyun Bae ,  Eunmi Hong ,  Tae-ho Jang ,  Sang Bum Kim ,  Seung Hoon Lee ,  Do-Hyun Nam

IPC分类号： C07D487/04 ,  A61P35/00 ,  A61P29/00 ,  A61P25/28 ,  A61K31/519

摘要： The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.

公开(公告)号：US20210267997A1

公开(公告)日：2021-09-02

申请号：US16488706

申请日：2018-02-23

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION ,  NATIONAL CANCER CENTER ,  SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

发明人： Hwan Geun Choi ,  Jong Bae Park ,  Eunhwa Ko ,  Jung Beom Son ,  Nam Doo Kim ,  Seung Hoon Lee ,  Do-Hyun Nam

IPC分类号： A61K31/5513 ,  A61K31/506 ,  A61K31/437 ,  A61K31/5377 ,  A61K31/4365 ,  A61K31/415 ,  C07K16/22 ,  A61P35/04

摘要： Disclosed is a pharmaceutical composition for the prevention or treatment of brain cancer, containing a compound capable of penetrating the blood-brain barrier as an active ingredient, the pharmaceutical composition for the prevention or treatment of brain cancer is capable of efficiently penetrating the blood-brain barrier of the brain to thereby effectively inhibit LRRK2 protein expression, and is thus useful in the prevention or treatment of brain cancer.

公开(公告)号：US20230181596A1

公开(公告)日：2023-06-15

申请号：US17953819

申请日：2022-09-27

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION ,  NATIONAL CANCER CENTER ,  SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

发明人： Hwan Geun Choi ,  Jong Bae Park ,  Eunhwa Ko ,  Jung Beom Son ,  Nam Doo Kim ,  Seung Hoon Lee ,  Do-Hyun Nam

IPC分类号： A61K31/5513 ,  A61P35/04 ,  A61K31/415 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/506 ,  A61K31/5377 ,  C07K16/22

CPC分类号： A61K31/5513 ,  A61P35/04 ,  A61K31/415 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/506 ,  A61K31/5377 ,  C07K16/22

摘要： Disclosed is a pharmaceutical composition for the prevention or treatment of brain cancer, containing a compound capable of penetrating the blood-brain barrier as an active ingredient, the pharmaceutical composition for the prevention or treatment of brain cancer is capable of efficiently penetrating the blood-brain barrier of the brain to thereby effectively inhibit LRRK2 protein expression, and is thus useful in the prevention or treatment of brain cancer.

公开(公告)号：US12077599B2

公开(公告)日：2024-09-03

申请号：US16767245

申请日：2018-03-06

申请人： Seoul National University R&DB Foundation ,  NATIONAL CANCER CENTER ,  THE ASAN FOUNDATION ,  University of Ulsan Foundation For Industry Cooperation

发明人： Junho Chung ,  Eugene C. Yi ,  Ji Eun Kim ,  Hwa Kyoung Lee ,  Junyeong Jin ,  Jong Bae Park ,  Hyori Kim

IPC分类号： C07K16/40 ,  G01N33/574

CPC分类号： C07K16/40 ,  G01N33/57423 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622

摘要： The present invention relates to an anti-ROS1 antibody improved in specificity for ROS1 and a use thereof and, more particularly, provides an anti-ROS1 antibody or an antigen-binding fragment thereof and a use thereof in cancer diagnosis.

公开(公告)号：US20210290570A1

公开(公告)日：2021-09-23

申请号：US17259013

申请日：2019-05-17

申请人： National Cancer Center

发明人： Soo Youl Kim ,  Jong Bae Park ,  Ho Lee ,  Hyon Chol Jang

IPC分类号： A61K31/155 ,  A61K31/11 ,  A61K31/44 ,  A61K31/437 ,  A61K31/4745 ,  A61K33/243 ,  A61K31/337 ,  A61K31/704 ,  A61P35/00

摘要： The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agenst capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.